BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Libevitug (HH-003) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Libevitug (HH-003)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07499544-9888@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20280912
DTEND;VALUE=DATE:20280913
SUMMARY:Libevitug (HH-003): Phase 3 readout est. (NCT07499544)
DESCRIPTION:Libevitug (HH-003)\, phase 3\, Chronic Hepatitis Delta.\nStudy:
  A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Par
 ticipants With Chronic HDV Infection (D-clear Study)\nEstimated primary co
 mpletion: 12 September 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/libevitug-hh-003#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07499544
URL:https://assetmemo.bio/drug/libevitug-hh-003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
